CHIP amplifies the risk of lymphoid malignancies in individuals with monoclonal B-cell lymphocytosis (MBL).

CHIP amplifies the risk of lymphoid malignancies in individuals with monoclonal B-cell lymphocytosis (MBL). Blood cancer journal Boddicker, N. J., Shanafelt, T. D., Parikh, S. A., Rabe, K. G., Griffin, R., Norman, A. D., Yao, Y., Tian, S., Ma, T., O'Brien, D. R., Vallejo, B. A., Hoel, M. S., Lehman, S. J., Olson, J. E., Hampel, P. J., Braggio, E., Patnaik, M. M., Cerhan, J. R., Vachon, C. M., Hanson, C. A., Slager, S. L. 2025; 15 (1): 195

Abstract

Monoclonal B-cell lymphocytosis (MBL) and clonal hematopoiesis of indeterminate potential (CHIP) are prevalent clonal precursors associated with increased risk of lymphoid malignancies. However, the relationship between MBL and CHIP and their combined impact on lymphoid malignancy risk remains poorly understood. We screened participants from the Mayo Clinic Biobank to identify MBL using eight-color flow cytometry; CHIP was detected using whole-exome sequencing of whole-blood DNA in 291 genes related to myeloid or lymphoid malignancies. Incident myeloid or lymphoid hematological malignancies were identified using ICD codes and confirmed via medical record review. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). Cox regression was used to estimate hazard ratios (HR). Analyses were adjusted for age and sex. In 10,067 participants, 15% had MBL, and 9% had CHIP. No evidence of an association between MBL and CHIP (OR?=?1.00; 95% CI: 0.82-1.20) was observed. With a median follow-up of 5.4 years, 138 participants developed hematological malignancies (94 lymphoid). MBL (HR?=?3.48; 95% CI: 2.27-5.34; P?

View details for DOI 10.1038/s41408-025-01385-8

View details for PubMedID 41198626

View details for PubMedCentralID PMC12592468